Clinical Trial Update: Safety Study of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetics in Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 safety study evaluating individual paclitaxel dose adjustment based on pharmacokinetics in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Caicun Zhou | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: UNKNOWN